Propel

Wishpond Marks First Anniversary of Propel IQ; Highlighting Lower Customer Churn Rates and Accelerating Customer Growth

Retrieved on: 
Tuesday, March 5, 2024
Propel, Marketing, Growth, Customer, LTV, SMS, MRR, Customer lifetime value, Customer attrition, Mobile phone

Launched in March 2023, Propel IQ is Wishpond's 'All-in-One' marketing platform built to serve all our customers' digital marketing needs.

Key Points: 
  • Launched in March 2023, Propel IQ is Wishpond's 'All-in-One' marketing platform built to serve all our customers' digital marketing needs.
  • Ali Tajskandar, CEO of Wishpond, commented, "Propel IQ is putting Wishpond on track for its next stage of growth.
  • Looking ahead, we anticipate the growth of Propel IQ to continue this trajectory and become a cornerstone for growth and profitability for Wishpond."
  • Up to 40% Lower Customer Churn: The customer churn rate for Propel IQ customers is between 30 and 40% lower in some cohorts compared to customers of other Wishpond solutions.

Statement on FTC Win Securing Temporary Block of IQVIA’s Acquisition of Propel Media

Retrieved on: 
Thursday, January 4, 2024
Federal Trade Commission, Food, Acquisition, Blog, News, Propel, Competition, FTC, Social media, Commission, District court, Tenet Healthcare

The federal court’s order in IQVIA is also a win for the FTC as it continues to challenge anticompetitive deals involving health care and emerging technology platforms.

Key Points: 
  • The federal court’s order in IQVIA is also a win for the FTC as it continues to challenge anticompetitive deals involving health care and emerging technology platforms.
  • We are pleased with the federal court’s decision and look forward to continuing to fight to permanently enjoin this anticompetitive deal via the Commission’s administrative proceedings.
  • The Commission also authorized FTC staff to seek a temporary restraining order and preliminary injunction in federal district court to prevent IQVIA from consummating its acquisition of Propel Media, pending the agency’s administrative proceeding.
  • For the latest news and resources, follow the FTC on social media, subscribe to press releases and read our blog.

Statement on FTC Win Securing Temporary Block of IQVIA’s Acquisition of Propel Media

Retrieved on: 
Wednesday, January 3, 2024
Federal Trade Commission, Food, Acquisition, Blog, News, Propel, Competition, FTC, Social media, Commission, District court, Tenet Healthcare

The federal court’s order in IQVIA is also a win for the FTC as it continues to challenge anticompetitive deals involving health care and emerging technology platforms.

Key Points: 
  • The federal court’s order in IQVIA is also a win for the FTC as it continues to challenge anticompetitive deals involving health care and emerging technology platforms.
  • We are pleased with the federal court’s decision and look forward to continuing to fight to permanently enjoin this anticompetitive deal via the Commission’s administrative proceedings.
  • The Commission also authorized FTC staff to seek a temporary restraining order and preliminary injunction in federal district court to prevent IQVIA from consummating its acquisition of Propel Media, pending the agency’s administrative proceeding.
  • For the latest news and resources, follow the FTC on social media, subscribe to press releases and read our blog.

Propel Software Extends the Digital Product Thread to Customer Assets Connecting Product, Commercial, and Service Operations

Retrieved on: 
Wednesday, December 6, 2023
IOT (Internet of Things), Building Systems, Other Professional Services, Construction & Property, Data Management, Manufacturing, Technology, Finance, Fintech, Consulting, Professional Services, Other Manufacturing, Other Technology, Software, Internet, Other Construction & Property, Cloud, GM, Internet of things, Engineering, CPO, PLM, Commerce, Acos, BOM, Savant syndrome, QMS, Marketing, DCOS, ERP, PVM, PIM, Digital thread, SFTP, Sony Professional Solutions, Gartner, Sales, Propel, Salesforce

Propel Software , creator of the first product value management (PVM) platform, expands the reach of its digital product thread throughout the enterprise with its latest PVM platform release.

Key Points: 
  • Propel Software , creator of the first product value management (PVM) platform, expands the reach of its digital product thread throughout the enterprise with its latest PVM platform release.
  • The company’s third major release in 2023 links customer assets with product lifecycle management (PLM) delivering deep intelligence on how products are used and perform in real-world scenarios.
  • This highly-valued product information gives companies the ability to refine design, improve quality, and drive greater lifetime customer value.
  • “This enables customers to execute their own IoT initiatives, tying operating data streams with associated product definition to drive new product offerings and improve the customer experience.

Lattice Continues Rapid Product Portfolio Expansion Enabling the Next Era of Innovation

Retrieved on: 
Tuesday, December 5, 2023
Data Management, Technology, Semiconductor, Security, Apps, Applications, Software, Artificial Intelligence, Networks, Internet, Hardware, Electronic Design Automation, Automotive industry, IP, Blog, DMA, Communication, Artificial intelligence, Marketing, Lattice Semiconductor, Conference, Data-rate units, 3D, AI, Computing, LSCC, Motion, Environment, LPDDR4, Video game, Sintering, Propel, FPGA, Radiant, Lattice

Today at the Lattice Developers Conference , Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, continued its rapid product portfolio expansion with the launch of multiple new hardware and software solutions.

Key Points: 
  • Today at the Lattice Developers Conference , Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, continued its rapid product portfolio expansion with the launch of multiple new hardware and software solutions.
  • Lattice introduced two new innovative mid-range FPGA device families built on the award-winning mid-range Lattice Avant™ platform – Lattice Avant™-G and Lattice Avant™-X, designed for general purpose and advanced connectivity, respectively.
  • Lattice Avant-G and Avant-X FPGAs are sampling today and are supported by the latest releases of Lattice Propel™ and Lattice Radiant™ design software.
  • Lattice today announced four solution stack updates in AI with Lattice sensAI™, embedded vision with Lattice mVision™, security with Lattice Sentry™, and factory automation with Lattice Automate™.

Wishpond Reports Continued Revenue and Adjusted EBITDA Growth in Q3-2023

Retrieved on: 
Thursday, November 16, 2023
Acquisition, Propel, Interim, Earnout, Bank statement, Acceleration, Research and development, Financial statement, Consultant, Marketing, Advertising, Social media, Adjustment, SEDAR, MD, Partnership, Software as a service, Growth, AI, MD Helicopters MD Explorer, MRR, SMB, Fiverr, Optimism, Bookkeeping, Beauty salon, Video game, Bank, Sales, Research

Wishpond achieved Adjusted EBITDA of $0.3 million, representing the fifth quarter in a row of positive Adjusted EBITDA.

Key Points: 
  • Wishpond achieved Adjusted EBITDA of $0.3 million, representing the fifth quarter in a row of positive Adjusted EBITDA.
  • Wishpond achieved revenue of $5.8 million in Q3-2023 and expects continued growth and improved cash flows in the last quarter of 2023.
  • Ali Tajskandar further adds, "In the third quarter we continued our streak of achieving positive Adjusted EBITDA for the fifth quarter in a row.
  • Wishpond's cost optimization efforts over the past year have contributed to the Company's continued positive Adjusted EBITDA profile.

On the Road to Halving Cancer: The 2023 Biotech Advancements Igniting Hope

Retrieved on: 
Wednesday, September 20, 2023
US Foods, Mantle cell lymphoma, IMGN, Congress, Prednisone, Patient, AstraZeneca, Risk, Prostate cancer, Propel, Eli Lilly and Company, Merck, Merck & Co., News, NYSE, Disease, White House, Monarchism in Iran, MRK, Hope, Mutation, ONC, TSX, FDA, Death, Prednisolone, Oncolytics Biotech, Eye, Cancer, ImmunoGen, PFS, BTK, Cancer Moonshot, BRCA, Ovarian cancer, ORR, Progression-free survival, RBC Capital Markets, OS, Paclitaxel, Quality of life, Pelareorep, MCL, Food, Breast cancer, Pharmaceutical industry, Birth control, Vaccine, Abemaciclib, Pirtobrutinib

VANCOUVER, British Columbia , Sept. 20, 2023 /PRNewswire/ -- USA News Group - Earlier this year, the US White House requested over $2.8 billion in funding from Congress for their  "Cancer Moonshot" initiative, an ambitious plan to slash cancer rates in half within the next quarter-century. Already, 2023 is brimming with encouraging progress in the biotech sector that is boosting our hope in the battle against cancer. Simplifying the jargon, this includes major breakthroughs in treatments that are prolonging the time before cancer worsens (known as progression-free survival or PFS) and increasing the rate at which patients respond positively to treatment (overall response rate or ORR). This inspiring progress has been led by companies like from Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Eli Lilly and Company, ImmunoGen, Inc. (NASDAQ: IMGN), Merck &Co., Inc. (NYSE: MRK), and AstraZeneca PLC (NASDAQ: AZN).

Key Points: 
  • Already, 2023 is brimming with encouraging progress in the biotech sector that is boosting our hope in the battle against cancer.
  • The trial, known as BRACELET-1, tested a therapy that combines the company's drug, pelareorep, with a common cancer treatment, paclitaxel.
  • In fact, the risk of the disease getting worse was reduced by an impressive 71% compared to paclitaxel alone, through its progression-free survival (PFS).
  • For patients, this could mean more time to enjoy life without the burden of worsening symptoms.

On the Road to Halving Cancer: The 2023 Biotech Advancements Igniting Hope

Retrieved on: 
Wednesday, September 20, 2023
US Foods, Mantle cell lymphoma, IMGN, Congress, Prednisone, Patient, AstraZeneca, Risk, Prostate cancer, Propel, Eli Lilly and Company, Merck, Merck & Co., News, NYSE, Disease, White House, Monarchism in Iran, MRK, Hope, Mutation, ONC, TSX, FDA, Death, Prednisolone, Oncolytics Biotech, Eye, Cancer, ImmunoGen, PFS, BTK, Cancer Moonshot, BRCA, Ovarian cancer, ORR, Progression-free survival, RBC Capital Markets, OS, Paclitaxel, Quality of life, Pelareorep, MCL, Food, Breast cancer, Pharmaceutical industry, Birth control, Vaccine, Abemaciclib, Pirtobrutinib

VANCOUVER, British Columbia, Sept. 20, 2023 /PRNewswire/ -- USA News Group - Earlier this year, the US White House requested over $2.8 billion in funding from Congress for their  "Cancer Moonshot" initiative, an ambitious plan to slash cancer rates in half within the next quarter-century. Already, 2023 is brimming with encouraging progress in the biotech sector that is boosting our hope in the battle against cancer. Simplifying the jargon, this includes major breakthroughs in treatments that are prolonging the time before cancer worsens (known as progression-free survival or PFS) and increasing the rate at which patients respond positively to treatment (overall response rate or ORR). This inspiring progress has been led by companies like from Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Eli Lilly and Company, ImmunoGen, Inc. (NASDAQ: IMGN), Merck &Co., Inc. (NYSE: MRK), and AstraZeneca PLC (NASDAQ: AZN).

Key Points: 
  • Already, 2023 is brimming with encouraging progress in the biotech sector that is boosting our hope in the battle against cancer.
  • The trial, known as BRACELET-1, tested a therapy that combines the company's drug, pelareorep, with a common cancer treatment, paclitaxel.
  • In fact, the risk of the disease getting worse was reduced by an impressive 71% compared to paclitaxel alone, through its progression-free survival (PFS).
  • For patients, this could mean more time to enjoy life without the burden of worsening symptoms.

Wishpond Announces Partnership with Fiverr Certified to Launch a Freelance Marketplace for Propel IQ

Retrieved on: 
Tuesday, September 5, 2023
Software as a service, Partnership, SMB, Propel, Tutoring, Fiverr

The partnership creates a unique freelance marketplace where Wishpond customers will be able to access certified professionals that can deliver marketing services for the Propel IQ platform.

Key Points: 
  • The partnership creates a unique freelance marketplace where Wishpond customers will be able to access certified professionals that can deliver marketing services for the Propel IQ platform.
  • Wishpond's partnership with Fiverr leverages 'Fiverr Certified' recently launched as part of Fiverr Business Solutions, where Fiverr will build a unique freelance marketplace for its tech partners.
  • The Fiverr Certified team will selectively scout skilled professionals and agencies, both internally and from Wishpond's existing partner network.
  • Furthermore, the partnership with Fiverr Certified is expected to bring forth a number of additional benefits for Wishpond.

LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone Approved in Japan for the Treatment of BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer

Retrieved on: 
Thursday, August 24, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, MSD, Prednisolone, Department of Urology, University of Virginia, HRR, NHA, NR, CI, Aes, OS, Cancer, MRK, Prognosis, RPF, AstraZeneca, Merck & Co., Prednisone, Death, HIV disease progression rates, Patient, Prostate cancer, Risk, Anemia, Propel, European, Nausea, BRCA, Metastasis, FDA, ITT, NYSE, Urology, Safety, Fatigue, Pharmaceutical industry, EU, Merck

As previously reported, there was a statistically significant improvement in rPFS in the full intention-to-treat (ITT) population in the PROpel trial (n=796).

Key Points: 
  • As previously reported, there was a statistically significant improvement in rPFS in the full intention-to-treat (ITT) population in the PROpel trial (n=796).
  • In the ITT population, common adverse events (AEs) in patients who received LYNPARZA plus abi/pred were anemia (45.5%), nausea (28.1%) and fatigue (27.9%).
  • Despite various treatment options available, the prognosis for mCRPC remains poor, with limited treatment options for patients whose cancer progresses following initial treatment.
  • This combination is also approved in the U.S. for the treatment of adult patients with deleterious or suspected deleterious BRCAm mCRPC.